United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

8:32pm BST
Change (% chg)

$-0.38 (-1.90%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Falberg, Kathryn 

Ms. Kathryn E. Falberg is Independent Director of the Company. She has served as a member of our Board since May 2015. She previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, a biopharmaceutical company, from March 2012 to March 2014, after serving as Senior Vice President and Chief Financial Officer since December 2009. From 2001 to 2009, Ms. Falberg worked with several smaller companies while serving as a corporate director and audit committee chair for several companies. From 1995 to 2001, Ms. Falberg was with Amgen Inc., a biotechnology company, where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer, and prior to that as Vice President, Chief Accounting Officer and Vice President, Treasurer. Ms. Falberg also serves as a member of the board of directors for biopharmaceutical companies UroGen Pharma Ltd. and Arcus Biosciences, and The Trade Desk, a technology company. She previously served on the board of directors of biotechnology companies Axovant Sciences Ltd., BioMarin Pharmaceutical, Inc., aTyr Pharma, Inc., Medivation, Inc., and Halozyme Therapeutics, Inc. Ms. Falberg received a B.A. in Economics and M.B.A. from the University of California, Los Angeles and is a certified public accountant (inactive). We believe that Ms. Falberg is qualified to serve on our Board due to her extensive background in financial and accounting matters for public companies and her leadership experience in the biotechnology industry.

Basic Compensation

Total Annual Compensation, USD 262,789
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 262,789

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --